Oncology and infectious disease diagnostics developer Biological Dynamics has been accepted to the Microsoft One Commercial Partner (OCP) program, which will enable it to use the development solutions available to OCP partners to help it establish a research service and delivery model.
Biological Dynamics is developing assays for pharmaceutical applications built on Verita, the company’s proprietary biomarker isolation technology that can isolate DNA and extracellular vesicles from plasma and serum without the need to pre-process samples.
“Our product development team has been using Microsoft Azure to host our data infrastructure and image analysis and we are excited to be accepted into this program and to receive access to Microsoft’s business capabilities as well,” said Raj Krishnan, Ph.D., CEO of Biological Dynamics, in a press release. “The combination of our diagnostic expertise with Microsoft’s global scale, intelligent capabilities and ecosystem of global partners will pave the way for significant enhancements in drug discovery and development applications.”
Founded in 2010, San Diego-based Biological Dynamics leverages research developed at UC San Diego’s Jacobs School of Engineering. The current focus of the company is on developing cancer and infectious disease diagnostics. In June of 2019, they received a grant from the Bill and Melinda Gates Foundation to develop a portable, smartphone-based diagnostic platform designed for use in areas without access to a traditional diagnostics laboratory. Acceptance to the OCP program will help continue the company’s development.
“Microsoft’s One Commercial Partner program and our Healthcare and Life Sciences team are focused on enabling our customers and partners to build high-value technologies that enable everyone greater access to personalized healthcare that is focused on better patient outcomes,” said Trent Norris, director of Life Science Partnership, Microsoft, in a prepared statement. “We see tremendous long-term potential in introducing exciting novel technologies into our partner ecosystem, supporting global drug discovery and development efforts.”
